This inventor holds 62 USPTO granted patents and 43 published patent applications, plus 1 CIPO patent and 17 EPO patents, primarily in RNA Therapeutics. Top assignees: Modernatx, Inc., Creative Technology Corporation, Fundacion Para La Investigacion Medica Aplicada. Active years: 1999-2025.
Location History:
- Santa Cruz, CA (US) (1999 - 2003)
- New York, NY (US) (2015)
- Cambridge, MA (US) (2021 - 2023)
- Brookline, MA (US) (2017 - 2024)
Company Filing History:
53 out of 246 
7 out of 554 
1 out of 10 
Years Active: 1999-2025
Areas of Expertise:
Title: Stephen G Hoge: Innovating mRNA Therapies for Cystic Fibrosis Treatment
Introduction:
In the realm of biomedical science, many individuals have dedicated their lives to transforming the landscape of healthcare. Among these forward-thinkers is Stephen G Hoge, a renowned innovator in mRNA therapy for the treatment of cystic fibrosis. His numerous patents and contributions have paved the way for groundbreaking advancements in this field. Let us delve into his latest patents, career highlights, collaborations, and the impact of his work.
Latest Patents:
Stephen G Hoge has an impressive portfolio of 43 patents, including his most recent innovations in mRNA therapy for cystic fibrosis treatment. One of his notable patents is titled "Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis." The invention focuses on utilizing mRNA to express cystic fibrosis transmembrane conductance regulator (CFTR) proteins, their isoforms, functional fragments, and fusion proteins. These mRNA therapies aim to increase or restore deficient levels of CFTR expression, leading to improved cystic fibrosis treatment outcomes. Furthermore, the patent highlights the use of lipid nanoparticles (LNPs) for effective delivery in vivo, enhancing the therapy's efficacy.
Another patent of significance is "RNA formulations," which explores the development of lipid-based compositions, including lipid nanoparticles, for efficient delivery of agents such as nucleic acids and proteins in vivo. These formulations present promising opportunities in delivering therapeutic molecules, opening new avenues for treating various diseases and disorders.
Career Highlights:
Stephen G Hoge has made substantial contributions to the field of mRNA therapy during his career. Holding key positions in Moderna, Inc. and Moderna Therapeutics, Inc., he has played a pivotal role in driving the development and implementation of groundbreaking biomedical technologies. Through his work, Hoge has spearheaded the advancement of mRNA-based therapies and their potential applications in treating cystic fibrosis, paving the way for other researchers and innovators.
Collaborations:
Throughout his journey, Stephen G Hoge has had the privilege of collaborating with exceptional individuals in his field. Notable colleagues include Kerry Benenato and Vladimir Presnyak, accomplished professionals who have contributed their expertise to the development of mRNA therapies for cystic fibrosis treatment. These collaborations have undoubtedly enriched the research landscape, fostering innovation and sharing of knowledge in pursuit of enhanced patient outcomes.
Conclusion:
Stephen G Hoge's dedication to biomedical innovation, particularly in the field of mRNA therapy for cystic fibrosis, has revolutionized the way we approach treatment options for this debilitating condition. With his extensive patent portfolio, including advancements in mRNA technology and innovative delivery systems, Hoge has provided a solid foundation for future developments in therapeutic interventions. His collaborations and career highlights demonstrate his unwavering commitment and invaluable contributions to the scientific community. Through his pioneering work, Hoge has laid the groundwork for improved treatments and brighter prospects for patients with cystic fibrosis.